The PDC's mechanism of entry does not rely upon specific molecular targets that are required and essential to the success of other targeted cancer therapies. Other targeted therapies require specific molecular targets on the cell surface. These molecular targets occur in very small numbers on the surface of cancer cells often are not present in all the cells within a tumor and may not be on cancer stem cells or on any metastatic sites at all. This means a subpopulation of cancer cells will always remain despite the targeted nature of other therapies. Additionally, a targeted therapy designed for one type of cancer often will not work on other cancer types because the specific molecule being targeted does not exist on other tumor types. This is the case with Antibody Drug Conjugates (ADC) whereby this 1:1 ratio result in delivering less than 1% of the cancer killing moiety to the tumor. Conversely, PDCs can target 100% of the tumor cells in a multitude of cancers in addition to delivering in excess of 25% of the cancer killing warhead directly to the cancer cells.
PDCs offer the potential advantage of possessing the ability to combine with molecules in numerous ways, thereby increasing the types of molecules that can be used and delivered via the PDCs, directly to tumor cells.
We approach drug discovery and development in a way that allows us to efficiently design, research and advance product candidates as quickly and safely as possible. We have successfully advanced our lead PDC, iopofosine, into three clinical studies evaluating over ten disease indications. Additionally, we have initiated multiple collaborations and internal proprietary programs that are currently ongoing.Product Pipeline
We aim to balance internal research and product development with academic collaboration and corporate partnering to advance our PLE technology platform and promising pipeline of oncology product candidates.Partnership Information